Status:
COMPLETED
Bioavailability Study for New Atorvastatin Formulation
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to estimate the relative bioavailability of the commercial tablet with one prototype extemporaneous preparation suspension formulation, to assist with internal decision ma...
Detailed Description
Estimation of Relative Bioavailability
Eligibility Criteria
Inclusion
- Healthy male and/or female subjects
- Body Mass Index (BMI) of approximately 18 to 30 kg/m2
Exclusion
- Any condition possibly affecting drug absorption
- A positive urine drug screening
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00844376
Start Date
February 1 2008
End Date
March 1 2008
Last Update
March 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511